| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SMARCA2 |
| Uniprot No | P51531 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 700-1216aa |
| 氨基酸序列 | SYYTVAHAISERVEKQSALLINGTLKHYQLQGLEWMVSLYNNNLNGILAD EMGLGKTIQTIALITYLMEHKRLNGPYLIIVPLSTLSNWTYEFDKWAPSV VKISYKGTPAMRRSLVPQLRSGKFNVLLTTYEYIIKDKHILAKIRWKYMI VDEGHRMKNHHCKLTQVLNTHYVAPRRILLTGTPLQNKLPELWALLNFLL PTIFKSCSTFEQWFNAPFAMTGERVDLNEEETILIIRRLHKVLRPFLLRR LKKEVESQLPEKVEYVIKCDMSALQKILYRHMQAKGILLTDGSEKDKKGK GGAKTLMNTIMQLRKICNHPYMFQHIEESFAEHLGYSNGVINGAELYRAS GKFELLDRILPKLRATNHRVLLFCQMTSLMTIMEDYFAFRNFLYLRLDGT TKSEDRAALLKKFNEPGSQYFIFLLSTRAGGLGLNLQAADTVVIFDSDWN PHQDLQAQDRAHRIGQQNEVRVLRLCTVNSVEEKILAAAKYKLNVDQKVI QAGMFDQKSSSHERRAF |
| 预测分子量 | 76 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SMARCA2重组蛋白的3篇参考文献及其摘要概括：
1. **"Structural and functional analysis of the SMARCA2 ATPase domain"**
- **作者**: Smith J, et al.
- **摘要**: 本研究通过重组表达纯化SMARTA2的ATP酶结构域，解析其晶体结构，揭示其与染色质重塑复合物结合的关键位点，并验证其ATP水解活性对基因调控的影响。
2. **"Recombinant SMARCA2 restores SWI/SNF complex function in SMARCA4-deficient cancer cells"**
- **作者**: Wang L, et al.
- **摘要**: 利用重组SMARCA2蛋白在SMARCA4缺失的癌细胞中恢复SWI/SNF复合体功能，证明其通过补偿机制抑制肿瘤生长，为靶向治疗提供实验依据。
3. **"High-yield expression and purification of human SMARCA2 for biochemical assays"**
- **作者**: Gonzalez R, et al.
- **摘要**: 开发了一种高效的大肠杆菌表达系统，优化重组SMARCA2蛋白的溶解性和稳定性，并验证其在体外染色质重塑实验中的功能性应用。
---
**注**：以上文献为示例，实际文献需通过PubMed或Web of Science检索关键词“SMARCA2 recombinant”或“BRM protein purification”获取。建议优先选择近五年内发表的、高影响因子期刊的研究。
SMARCA2. also known as BRM (Brahma homolog), is a member of the SWI/SNF (switch/sucrose non-fermentable) family of ATP-dependent chromatin-remodeling complexes. These complexes regulate gene expression by altering chromatin structure, enabling access to transcription factors and other DNA-associated proteins. SMARCA2 functions as a catalytic ATPase subunit within the SWI/SNF complex, facilitating nucleosome repositioning and modulating transcriptional activity. It shares functional redundancy with its paralog, SMARCA4 (BRG1), though their roles can diverge in specific tissues or developmental contexts.
Recombinant SMARCA2 protein is engineered for in vitro studies to dissect its biochemical properties, structural features, and interactions. Produced using heterologous expression systems (e.g., bacteria, insect, or mammalian cells), the recombinant protein retains ATPase activity and chromatin-binding capacity, enabling researchers to explore its role in DNA repair, differentiation, and tumor suppression. Dysregulation of SMARCA2 is linked to cancers, neurodevelopmental disorders, and other diseases, making it a target for mechanistic and therapeutic studies.
Research on recombinant SMARCA2 has advanced understanding of its modular domains, including the conserved helicase ATP-binding and C-terminal bromodomain, which mediate chromatin targeting and enzymatic activity. Structural studies using recombinant proteins have revealed conformational changes during ATP hydrolysis and nucleosome engagement. Challenges persist in reconstituting full-length SMARCA2 due to its size and post-translational modifications, prompting the use of truncated variants for functional assays. Additionally, SMARCA2’s functional overlap with SMARCA4 complicates studies, requiring precise experimental designs to isolate its unique contributions. Recombinant SMARCA2 remains a critical tool for probing SWI/SNF complex dynamics and developing targeted therapies for diseases linked to chromatin remodeling defects.
×
